Chairperson(s) : Jung-Hyun Noh (Inje University, Republic of Korea), Byung-Wan Lee (Yonsei University, Republic of Korea),
Panel(s) : Shinae Kang (Yonsei University, Republic of Korea), Osung Kwon (The Catholic University of Korea, Republic of Korea), Dae Young Cheon (Hallym University, Republic of Korea)
-
Efficacy and safety of tirzepatide, a GIP and GLP-1 dual agonist, in persons with type 2 diabetes
Yasuo Terauchi Yokohama City University, Japan 08:50~09:10 -
Upcoming multi-agonists for cardio-metabolic disease
Chang Hee Jung University of Ulsan, Republic of Korea 09:10~09:30 -
A potential mechanism of a dual GLP-1/GIP receptor agonist
Yong-ho Lee Yonsei University, Republic of Korea 09:30~09:50 - Panel Discussion 09:50~10:20
Chairperson(s) : Byung Jin Kim (Sungkyunkwan University, Republic of Korea), Young Joon Hong (Chonnam National University, Republic of Korea)
Panel(s) : Je Sang Kim (Bucheon Sejong Hospital, Republic of Korea), Ye Seul Yang (Seoul National University, Republic of Korea), Hye Jin Yoo (Korea University, Republic of Korea)
-
How does remnant cholesterol related to cardiometabolic multimorbidity
Jun Hwa Hong Eulji University, Republic of Korea 15:40~16:00 -
Epidemiologic evidence of hyper TG or remnant cholesterol on CVD
Donna Shu-Han Lin Shin Kong Wu Ho-Su Memorial Hospital, Taiwan 16:00~16:20 -
Treatments targeting remnant cholesterol or hyperTG in Asians: do we have an option?
Youngwoo Jang Gachon University, Republic of Korea 16:20~16:40 - Panel Discussion 16:40~17:10
